Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer

Gynecologic Oncology

Volumn 115, Issue 3, 2009, Pages 396-400

  Hurt, J D ^a   Richardson, D L ^a   Seamon, L G ^a   Fowler, J F ^a   Copeland, L J ^a   Cohn, D E ^a   Eisenhauer, E ^a   Salani, R ^a   O'Malley, D M ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Biologics; Chemotherapy; Monoclonal antibodies; Ovarian cancer

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PLATINUM; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; DRUG EFFICACY; EPITHELIAL OVARY CANCER; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE PERFORATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 70350566692     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.08.032     Document Type: Article

References (24)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Young R.C., Decker D.G., Wharton J.T., Piver M.S., Sindelar W.F., Edwards B.K., and Smith J.P. Staging laparotomy in early ovarian cancer. Jama 250 (1983) 3072-3076
3. Markman M. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. Trends Pharmacol. Sci. 29 10 (2008) 515-519
4. Richardson D.L., Backes F.J., Seamon L.G., Zanagnolo V., O'Malley D.M., Cohn D.E., Fowler J.M., and Copeland L.J. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol. Oncol. 111 3 (2008) 461-466
5. Cohn D.E., Valmadre S., Resnick K.E., Eaton L.A., Copeland L.J., and Fowler J.M. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol. Oncol. 102 (2006) 134-139
6. Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., Mackey H., Douglas J., Burger R.A., Armstrong D., Wenham R., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25 (2007) 5180-5186
7. Spannuth W.A., Sood A.K., and Coleman R.L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat. Clin. Pract. Oncol. 5 (2008) 194-204
8. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol. Oncol. 101 (2006) 436-440
9. Linch M., Stavridi F., Hook J., Barbachano Y., Gore M., and Kaye S.B. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer. Gynecol. Oncol. 109 (2008) 27-32
10. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (2007) 5165-5171
11. Chura J.C., Van Iseghem K., Downs Jr. L.S., Carson L.F., and Judson P.L. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol. Oncol. 107 (2007) 326-330
12. CTCAE. http://ctep.cancer.gov/forms/CTCAEv3.pdf.
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
14. Guppy A.E., and Rustin G.J. CA125 response: can it replace the traditional response criteria in ovarian cancer?. Oncologist 7 (2002) 437-443
15. Lee J.J., and Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J. Clin. Oncol. 24 (2006) 1633-1642
16. Dunder I., Berker B., Atabekoglu C., and Bilgin T. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. Eur. J. Gynaecol. Oncol. 26 (2005) 79-82
17. Genentech Provides Update on Phase II Study with Avastin in Platinum-Refractory Ovarian Cancer. http://www.gene.com/gene/news/press-releases/display.do?method=detail and id=8907.
18. Seewaldt V.L., Cain J.M., Goff B.A., Tamimi H., Greer B., and Figge D. A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. Gynecol. Oncol. 67 (1997) 137-140
19. Monk B.J., Han E., Josephs-Cowan C.A., Pugmire G., and Burger R.A. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 102 (2006) 140-144
20. Wright J.D., Hagemann A., Rader J.S., Viviano D., Gibb R.K., Norris L., Mutch D.G., and Powell M.A. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107 (2006) 83-89
21. Simpkins F., Belinson J.L., and Rose P.G. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol. Oncol. 107 (2007) 118-123
22. Korbel R.S., and Kamen B.A. The antipangiogenesis basis of metronomic chemotherapy. Nat. Rev. Cancer 4 6 (2004 Jun) 423-436
23. Kamat A.A., Tae J.K., Landen C.N., Lu C., Han L.Y., Lin Y.G., Merritt W.M., Thacker P.H., Gershenson D.M., Bischoff F.Z., Heymach J.V., Jaffe R.B., Coleman R.L., and Sood A.K. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 67 1 (2007) 281-288
24. Micha J.P., Goldstein B.H., Rettenmaier M.A., Genesen M., Graham C., Bader K., Lopez K.L., Nickle M., and Brown III J.V. A phase II study of outpatient first line paclitaxel, carboplatin, and Bevacizumab for advanced-stage epithelial ovarian, peritonel and fallopian tube cancer. Int. J. Gynecol. Cancer 17 4 (2007 Jul-Aug) 771-776